NEW YORK, July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

Core Viewpoint - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, alleging material misstatements and omissions that led to investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Rocket Pharmaceuticals stock between September 17, 2024, and May 26, 2025 [2]. - The lawsuit claims that Rocket Pharmaceuticals failed to disclose significant safety-related updates regarding its RP-A501 clinical trial, including the use of an immunomodulatory agent, prior to a fatal adverse event and subsequent FDA-imposed clinical hold [3]. - Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' shares plummeted from $6.27 to $2.33 [3]. Group 2: Company Overview - Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and specializes in gene therapies for rare and life-threatening diseases [2].

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. If you purchased shares of Rocket Pharmaceuticals between February 27, 202 ...

NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs ...

CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts conc ...

Core Insights - Rocket Pharmaceuticals (RCKT) has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy candidate RP-A601, aimed at treating PKP2-arrhythmogenic cardiomyopathy (ACM) [1][7] - The RMAT designation allows for enhanced interactions with the FDA, facilitating accelerated approval processes and early discussions on potential endpoints [2] Company Developments - Following the RMAT announcement, RCKT's shares increased by 16.8%, although the stock has decreased by 73.5% year-to-date, contrasting with a 0.7% decline in the industry [3] - The FDA's RMAT designation was based on positive safety and efficacy data from a phase I study, which indicated that RP-A601 is generally safe and well-tolerated [4][7] - RCKT is also developing another gene therapy candidate, RP-A701, for BAG3-associated dilated cardiomyopathy (BAG3-DCM), with the FDA recently approving its investigational new drug application [5][8] Recent Challenges - The company faced setbacks, including a voluntary pause in the pivotal phase II study of RP-A501 for Danon disease due to a patient death, leading to an FDA clinical hold [9] - Additionally, the FDA issued a complete response letter regarding the BLA for Kresladi, requesting more information on Chemistry Manufacturing and Controls, which has delayed the review process [10]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths, during the clinical trials [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about RP-A501's safety while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day. Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder. Since the May 27 announcement, a ...

PHILADELPHIA, July 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket Pharmaceuticals” or the “Company”) for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses. Rocket Pharmaceuticals is headquartered in Cranbury, New J ...